Oxurion N.V. (TBGNF) Research

Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline includes THR-149, a plasma kallikrein inhibitor currently in Phase II development for diabetic macular edema (DME), and THR-687, an integrin antagonist also undergoing Phase II trials for DME. Oxurion maintains strategic collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company adopted its current name, Oxurion NV, in September 2018, having previously been known as ThromboGenics NV.

Market snapshot

Symbol
TBGNF
Price
$0.17
Day change
0.00%
Market cap
$266.4K
P/E ratio
-0.03x
52-week range
0.17-2.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Columbia Care Inc. (CCHWF)
  • Opthea Limited (CKDXF)
  • NIOX Group Plc (CSSPF)
  • Dong Fang Hui Le Inc. (DFHL)
  • Inventiva S.A. (IVEVF)
  • Orpea S.A. (ORRRY)
  • PT Tempo Scan Pacific Tbk (PEXXF)
  • PeakBirch Commerce Inc. (PKBFF)

Open Oxurion N.V. (TBGNF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.